Lysosomal storage disorders may not sound as dire as diseases such as cancer or Alzheimer’s, but to the people that suffer from them, life can be a nightmare. In fact, three of the primary disorders in this category—Gaucher’s Disease, Fabry Disease, and Pompe Disease—aren’t only characterized by a variety of painful, lifelong symptoms, they can ultimately lead to lung and kidney problems, stroke, heart attacks, muscle weakness, and, in some cases, death.

It’s rare conditions like these that are at the heart of the mission undertaken every day by the therapeutics division of Genzyme, a global biotechnology company. At the company’s manufacturing facility located in Allston, Massachusetts, medicines for treating three distinct lysosomal storage disorders are produced:

 …